Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Verquvo
Vericiguat is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction. It is a novel oral therapy that works by enhancing the effects of nitric oxide, a key regulator of cardiovascular function. Vericiguat belongs to the class of sGC stimulators and represents a new approach to managing heart failure by improving cardiac output and reducing cardiac workload.
Vericiguat is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with symptomatic chronic heart failure and reduced ejection fraction.
Outcome:
Increased vericiguat levels
Mechanism:
CYP3A4 inhibition
Outcome:
Decreased vericiguat levels
Mechanism:
CYP3A4 induction
Outcome:
Slightly decreased vericiguat absorption
Mechanism:
Altered gastric pH
Most likely new formulation: Combination therapy with sacubitril/valsartan (2025, 80% confidence)
Based on current usage and clinical trial data, there is a 70% likelihood of vericiguat remaining a first-line therapy for chronic heart failure with reduced ejection fraction over the next 5 years.
Heart Failure Medications, Soluble Guanylate Cyclase Stimulator
Pyrazolopyridine